# REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

Study · id `cardio:ct-nct07213778` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07213778](<https://clinicaltrials.gov/study/NCT07213778>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07213778

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT07213778. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-24 (actual); primary completion 2027-05-17 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT07213778, source copy `cardio:ctgov-nct07213778-2026-11-05`, retrieved 2026-11-18)
- Started: 2025-11-24 (actual) (ClinicalTrials.gov record NCT07213778, source copy `cardio:ctgov-nct07213778-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2027-05-17 (anticipated) (ClinicalTrials.gov record NCT07213778, source copy `cardio:ctgov-nct07213778-2026-11-05`, retrieved 2026-11-18)
- Completion: 2027-07-16 (anticipated) (ClinicalTrials.gov record NCT07213778, source copy `cardio:ctgov-nct07213778-2026-11-05`, retrieved 2026-11-18)
- Countries: United States; Greece; Malaysia; Moldova; Spain (ClinicalTrials.gov record NCT07213778, source copy `cardio:ctgov-nct07213778-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07213778-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
- Acronym: ROXI-ASPEN
- Condition: Symptomatic Venous Thromboembolism (VTE)
- Intervention (Drug): REGN7508
- Intervention (Drug): Acetylsalicylic Acid (ASA)
- Intervention (Drug): Placebo
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: 7f1801d54ed89576e244be5e716260300c0c23730a13d5b694e3dd25bd611466
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
